In this article we review the basis for current anti-mitotic, anti-cancer, therapy and the potential for Aurora B kinase inhibitors as a new differentiated class of agents--"mitotic drivers". We review the current understanding of Aurora B inhibition from basic cell biology to inhibitors currently undergoing clinical trials.
No takes yet. Share an insight, caveat, or question.
Keen et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: